Should I buy or sell Cytokinetics stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CYTK shares. View CYTK analyst ratings or view top-rated stocks .

What is Cytokinetics' stock price target for 2024?

15 Wall Street analysts have issued 12-month price targets for Cytokinetics' stock. Their CYTK share price targets range from $50.00 to $108.00. On average, they anticipate the company's stock price to reach $79.33 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price. View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts .

How have CYTK shares performed in 2024?

Cytokinetics' stock was trading at $83.49 at the beginning of 2024. Since then, CYTK shares have decreased by 19.8% and is now trading at $67.00. View the best growth stocks for 2024 here .

Are investors shorting Cytokinetics?

Cytokinetics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 13,230,000 shares, a decrease of 10.6% from the March 15th total of 14,800,000 shares. Based on an average daily trading volume, of 3,170,000 shares, the days-to-cover ratio is currently 4.2 days. Currently, 13.3% of the company's stock are sold short. View Cytokinetics' Short Interest .

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CYTK earnings forecast .

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) announced its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.03) by $0.35. The biopharmaceutical company earned $1.70 million during the quarter, compared to the consensus estimate of $7.62 million. The business's revenue was down 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.45) EPS.

What ETFs hold Cytokinetics' stock?

ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Fidelity Disruptive Medicine ETF (FMED) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) , SPDR S&P Biotech ETF (XBI) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) , Harbor Health Care ETF (MEDI) , BNY Mellon Innovators ETF (BKIV) , American Century Mid Cap Growth Impact (MID) and Principal Healthcare Innovators ETF (BTEC) .

What guidance has Cytokinetics issued on next quarter's earnings?

Cytokinetics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com . Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA) , Arena Pharmaceuticals (ARNA) , OncoSec Medical (ONCS) , Novavax (NVAX) , Amgen (AMGN) , Inovio Pharmaceuticals (INO) , Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , TherapeuticsMD (TXMD) and Gilead Sciences (GILD) .

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Mirador Capital Partners LP (0.03%), State of Michigan Retirement System (0.02%), Los Angeles Capital Management LLC (0.02%), Wealth Enhancement Advisory Services LLC (0.01%), Cannon Global Investment Management LLC (0.01%) and First Bank & Trust (0.01%). Insiders that own company stock include B Lynne Parshall , Ching Jaw , David Cragg , Edward M Md Kaye , Fady Ibraham Malik , John T Henderson, L Patrick Gage , Mark A Schlossberg , Muna Bhanji , Robert I Blum, Robert I Blum , Robert Wong , Sandford D Smith, Sandford D Smith , Santo J Costa and Wendall Wierenga . View institutional ownership trends .

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:CYTK

Cytokinetics (CYTK) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free CYTK Stock Alerts

$67.00

-0.93 (-1.37%)

(As of 04/18/2024 ET)

Compare

Today's Range: $66.84
▼
$68.53
50-Day Range: $63.75
▼
$80.99
52-Week Range: $25.98
▼
$110.25

Volume: 894,737 shs
Average Volume: 3.04 million shs
Market Capitalization: $7.01 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $79.33

Get Cytokinetics alerts:

Cytokinetics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.87 Rating Score
Upside/Downside: 18.4% Upside
$79.33 Price Target
Short Interest: Healthy
13.33% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.83
Upright™ Environmental Score
News Sentiment: 1.16
Based on 4 Articles This Week
Insider Trading: Selling Shares
$9.61 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.50) to ($3.17) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.87 out of 5 stars

Medical Sector

198th out of 918 stocks

Pharmaceutical Preparations Industry

74th out of 402 stocks

3.4

Analyst's Opinion

Consensus Rating
Cytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cytokinetics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
13.33% of the float of Cytokinetics has been sold short.
Short Interest Ratio / Days to Cover
Cytokinetics has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in Cytokinetics has recently decreased by 10.61%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Cytokinetics does not currently pay a dividend.
Dividend Growth
Cytokinetics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Cytokinetics has received a 71.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Cytokinetics is -0.83.

2.3

News and Social Media Coverage

News Sentiment
Cytokinetics has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Cytokinetics this week, compared to 6 articles on an average week.
Search Interest
Only 7 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,605,955.00 in company stock.
Percentage Held by Insiders
Only 3.80% of the stock of Cytokinetics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cytokinetics are expected to grow in the coming year, from ($4.50) to ($3.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cytokinetics is -12.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cytokinetics is -12.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Cytokinetics Stock (NASDAQ:CYTK)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CYTK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CYTK Stock News Headlines

April 10, 2024 | insidertrades.com

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $2,422,877.55 in Stock

April 15, 2024 | americanbankingnews.com

Cytokinetics, Incorporated (NASDAQ:CYTK) Sees Large Decline in Short Interest

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 11, 2024 | uk.investing.com

Cytokinetics to present phase 3 trial results for heart drug at Heart Failure 2024

April 11, 2024 | uk.investing.com

Cytokinetics EVP sells over $2.4m in company stock

April 10, 2024 | globenewswire.com

Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

April 10, 2024 | globenewswire.com

Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

April 10, 2024 | americanbankingnews.com

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 32,605 Shares

April 19, 2024 | InvestorPlace (Ad)

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 10, 2024 | americanbankingnews.com

Cytokinetics (NASDAQ:CYTK) Receives "Buy" Rating from Needham & Company LLC

April 9, 2024 | finance.yahoo.com

EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)

April 9, 2024 | americanbankingnews.com

Truist Financial Reaffirms "Buy" Rating for Cytokinetics (NASDAQ:CYTK)

April 5, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Cytokinetics Amid Strong Aficamten Trial Results

April 5, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Cytokinetics Amid Promising Aficamten Clinical Results

April 5, 2024 | globenewswire.com

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session

April 3, 2024 | benzinga.com

$100 Invested In Cytokinetics 5 Years Ago Would Be Worth This Much Today

April 2, 2024 | globenewswire.com

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2024 | globenewswire.com

Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024 | seekingalpha.com

Cytokinetics, Incorporated: Buyout Speculation Persists

March 30, 2024 | finance.yahoo.com

CYTK Apr 2024 60.000 call

March 27, 2024 | msn.com

Cytokinetics gains amid renewed takeover speculation

March 25, 2024 | globenewswire.com

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session

March 18, 2024 | investorplace.com

7 Biotech Stocks Ready to Ride the Sector's Resurgence

March 16, 2024 | finance.yahoo.com

CYTK Mar 2024 63.000 call

March 15, 2024 | finance.yahoo.com

CYTK Mar 2024 69.000 put

March 15, 2024 | finance.yahoo.com

CYTK Mar 2024 69.000 call

March 15, 2024 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Amedisys (AMED), Cytokinetics (CYTK) and Coherus Biosciences (CHRS)

See More Headlines

Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CYTK
CUSIP: N/A
CIK: 1061983
Web: www.cytokinetics.com
Phone: (650) 624-3000
Fax: 650-624-3010
Employees: 423
Year Founded: 1997

Price Target and Rating

Average Stock Price Target: $79.33
High Stock Price Target: $108.00
Low Stock Price Target: $50.00
Potential Upside/Downside: +18.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.87
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-526,240,000.00
Net Margins: -6,988.63%
Pretax Margin: -6,988.63%
Return on Equity: N/A
Return on Assets: -65.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.12
Quick Ratio: 6.12

Sales & Book Value

Annual Sales: $7.53 million
Price / Sales: 930.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.94) per share
Price / Book: -17.01

Miscellaneous

Outstanding Shares: 104,580,000
Free Float: 100,602,000
Market Cap: $7.01 billion
Optionable: Optionable
Beta: 0.68

Social Links

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Robert I. Blum (Age 60)
CEO, President & Director
Comp: $1.14M
Mr. Robert C. Wong (Age 56)
VP & Chief Accounting Officer
Comp: $463.75k
Dr. Fady Ibraham Malik FACC (Age 60)
M.D., Ph.D., Executive Vice President of Research & Development
Comp: $776.99k
Mr. Andrew M. Callos (Age 68)
Executive VP & Chief Commercial Officer
Comp: $745.4k
Dr. James A. Spudich Ph.D. (Age 82)
Co-Founder & Member of Scientific Advisory Board
Comp: $21.94k
Mr. Jeff Lotz
Vice President of Sales & Operations
Mr. Matt Yang
Vice President of Corporate Finance and Financial Planning & Analysis
Mr. Steven M. Cook (Age 65)
Senior Vice President of Global Supply Chain Operations & Technical Operations
Dr. Stuart Kupfer M.D.
Senior VP & Chief Medical Officer
Mr. Eric Terhaerdt
Senior Vice President of Development Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CYTK Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CYTK shares.
View CYTK analyst ratings or view top-rated stocks.
What is Cytokinetics' stock price target for 2024?: 15 Wall Street analysts have issued 12-month price targets for Cytokinetics' stock. Their CYTK share price targets range from $50.00 to $108.00. On average, they anticipate the company's stock price to reach $79.33 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts.
How have CYTK shares performed in 2024?: Cytokinetics' stock was trading at $83.49 at the beginning of 2024. Since then, CYTK shares have decreased by 19.8% and is now trading at $67.00.
View the best growth stocks for 2024 here.
Are investors shorting Cytokinetics?: Cytokinetics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 13,230,000 shares, a decrease of 10.6% from the March 15th total of 14,800,000 shares. Based on an average daily trading volume, of 3,170,000 shares, the days-to-cover ratio is currently 4.2 days. Currently, 13.3% of the company's stock are sold short.
View Cytokinetics' Short Interest.
When is Cytokinetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CYTK earnings forecast.
How were Cytokinetics' earnings last quarter?: Cytokinetics, Incorporated (NASDAQ:CYTK) announced its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.03) by $0.35. The biopharmaceutical company earned $1.70 million during the quarter, compared to the consensus estimate of $7.62 million. The business's revenue was down 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.45) EPS.

What ETFs hold Cytokinetics' stock?: ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Fidelity Disruptive Medicine ETF (FMED), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Harbor Health Care ETF (MEDI), BNY Mellon Innovators ETF (BKIV), American Century Mid Cap Growth Impact (MID) and Principal Healthcare Innovators ETF (BTEC).
What guidance has Cytokinetics issued on next quarter's earnings?: Cytokinetics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million.
What is Robert I. Blum's approval rating as Cytokinetics' CEO?: 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.
What other stocks do shareholders of Cytokinetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).
Who are Cytokinetics' major shareholders?: Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Mirador Capital Partners LP (0.03%), State of Michigan Retirement System (0.02%), Los Angeles Capital Management LLC (0.02%), Wealth Enhancement Advisory Services LLC (0.01%), Cannon Global Investment Management LLC (0.01%) and First Bank & Trust (0.01%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends.
How do I buy shares of Cytokinetics?: Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYTK) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial